Desselle Mathilde R, Neale Ruth, Hansford Karl A, Zuegg Johannes, Elliott Alysha G, Cooper Matthew A, Blaskovich Mark At
Community for Open Antimicrobial Drug Discovery, Institute for Molecular Bioscience, The University of Queensland, Brisbane QLD 4072, Australia.
Future Sci OA. 2017 Mar 24;3(2):FSO171. doi: 10.4155/fsoa-2016-0093. eCollection 2017 Jun.
The Community for Open Antimicrobial Drug Discovery (CO-ADD) is a not-for-profit, collaborative approach to discovering new antibiotics. We access novel chemical diversity from academic synthetic chemists, who collectively possess millions of untested compounds with chemical diversity that lie outside commercial collections. We perform high-throughput antimicrobial screening of pure compounds derived from both synthetic and natural sources free of charge. The resulting data can be used by participants for publication, patenting and development purposes, and is fed back into the research community through an open-access database after a 2-year period during which information is kept confidential to the provider. CO-ADD is fundamentally asking two questions: can the community work together to address the global threat of antimicrobial resistance; and are there as yet undiscovered, novel antimicrobial compounds already present within our diverse global chemistry community?
开放抗菌药物发现社区(CO-ADD)是一种用于发现新型抗生素的非营利性协作方法。我们从学术合成化学家那里获取新型化学多样性,他们总共拥有数百万种未经测试的具有化学多样性的化合物,这些化合物不在商业收藏范围内。我们免费对源自合成和天然来源的纯化合物进行高通量抗菌筛选。所得数据可供参与者用于发表、专利申请和开发目的,并在对提供者保密两年后,通过一个开放获取数据库反馈给研究社区。CO-ADD从根本上提出了两个问题:社区能否共同应对全球抗微生物药物耐药性威胁;在我们多样化的全球化学社区中是否已经存在尚未被发现的新型抗菌化合物?